Rising home prices and conservative borrowing have today's homeowners sitting on a record amount of potential cash. Today's mortgage holders saw their home equity increase by...Real Estateread more
Stocks have been grinding sideways, but technical analysts say once they breakout, the move to the upside could be powerful.Market Insiderread more
The fresh round of cuts is on top of an estimated 4,500 temporary layoffs GM and its suppliers handed out to employees as of Friday.Autosread more
The new wireless earbuds, codenamed "Puget," are expected to come with an accelerometer and be able to monitor things like the distance run, calories burned, and pace of...Technologyread more
Think about the last TV show you recommended to a friend, or the last one that was recommended to you. Odds are, it was from a premium service like HBO, Netflix or Amazon.Entertainmentread more
SpaceX is deep into development of its Starship rocket, with recent updates from CEO Elon Musk showing the first one under construction.Investing in Spaceread more
Greta Thunberg, a 16-year-old Swedish environmental activist, delivered a powerful message at the United Nations Climate Action Summit on Monday.Environmentread more
The Mac Pro is the only major Apple computer to be assembled in the United States. Most of Apple's products, including the iPhone, are assembled in China and are facing tariff...Technologyread more
SoftBank wants to push Neumann out of the CEO role ahead of the IPO.Technologyread more
Toys R Us' bankruptcy caused a 7% surge in sales for the toy industry during the first half of 2018 as parents stocked up, then sales fell 2% as manufacturers experienced...Retailread more
After an unexpected loss of subscribers and increased competition in the streaming war, shares of Netflix erased all of its 46% gain for the year at its peak and officially...Marketsread more
Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over Kite's Friday close. Kite's shares were trading up at $178.15 before the bell.
Santa Monica, California-based Kite is developing a CAR-T, or chimeric antigen receptor T-cell therapy, which harnesses the body's own immune cells to recognize and attack malignant cells.
Gilead's growth has been fueled by its pricey but revolutionary hepatitis C drugs but with fewer eligible patients and rising competition, sales have begun to fall.
Second-quarter sales of its hepatitis C drugs — Sovaldi, Harvoni and Epclusa — totaled $2.9 billion, down from $4 billion a year earlier.
Wall Street and Gilead shareholders have long been expecting Gilead to use its cash pile for a big-ticket acquisition.
The deal for Kite, which has been approved by the boards of both companies, is expected to close in the fourth quarter.
If approved, these drugs are expected to cost up to $500,000 and generate billions of dollars. Success would also help advance a cancer-fighting technique that scientists have been trying to perfect for decades.
The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to approve Kite's CAR-T, axi-cel, for treatment of adults with advanced lymphoma.
Gilead has a market value of $96.36 billion, according to Thomson Reuters data. The company was once the world's largest maker of HIV drugs, and in 2011 agreed to acquire hep C drug developer Pharmasset for $11 billion.
Last year, Gilead generated total sales of $30.39 billion, of which $14.8 billion came from hep C treatments.
Bank of America/Merrill Lynch and Lazard are acting as financial advisers to Gilead, while Centerview Partners is Kite's exclusive financial adviser.
Skadden, Arps, Slate, Meagher & Flom is the legal counsel to Gilead and Sullivan & Cromwell and Cooley for Kite.
The Wall Street Journal reported first reported the deal.
Gilead's shares were little changed in premarket trading, while Juno's shares rose nearly 14 percent and Bluebird's 2.6 percent.